What tirzepatide's dual-agonist mechanism does Tirzepatide is a GIP/GLP-1 dual agonist, meaning it engages two incretin pathways rather than the single GLP-1 receptor that agonists like semaglutide target
At baseline, HIT-6 scores were significantly higher in the exenatide arm, and neither HIT-6 nor SF-36 showed significant changes over the course of the trial
Dietary therapy should focus on high carbohydrates and medium-chain triglycerides (which dont require the carnitine cycle) and a lower intake of long-chain fatty acids
When interpreting the data, possible contraindications must also be taken into account, which were not explicitly addressed for reasons of clarity of this study
Conversely, liraglutide failed to alter survival or pathology in SOD1G93A and TDP-43Q331K mice, underscoring uncertainty over molecule choice, dosing, and CNS penetration (168)
2000 Oct;136(4):270-6